MUST READS 

An October 17, 2016 Las Vegas Review-Journal article reported that “Dr. Jeffrey Cummings, says the 2025 target date set by world leaders for prevention and treatment of the disease is in jeopardy unless drug development can be accelerated.” According to the article, “It’s an elusive goal, he said as he talked Monday about a paper he recently published in Alzheimer’s Research and Therapy. The paper suggested ways to move trial drugs faster through the approval process, including cutting the FDA’s review of the efficacy of a drug from 18 months to six months.” Dr. Jerffrey Cummings is the medical director of the Cleveland Clinic Lou Ruvo Center for Brain Health.

An October 17, 2016 Motely Fool article highlighted the continued focus on Alzheimer’s from big drug makers. According to the article, “Big Pharma and biotech kicked off 2016 with a noteworthy 77 experimental compounds in development for AD, according to the Pharmaceutical Research and Manufacturers of America. Among this diverse list of clinical hopefuls, Eli Lilly (NYSE:LLY) and Biogen's (NASDAQ:BIIB) beta-amyloid plaque-busting antibodies -- solanezumab and aducanumab, respectively -- have garnered the most attention of late, in part because of the advanced state of their development.”

REGIONAL SPOTLIGHT 

An October 18, 2016 83 Degrees article highlighted the University of South Florida’s Byrd Alzheimer's Mobile Research Suite. According to Dr. Amanda Smith, Medical Director at USF Health, “By bringing research trials to their communities and making it convenient for them to participate, we can fill studies faster with the ultimate goal of bringing new treatments to the market sooner.”

An October 17, 2016 Winona Daily News article reported that “The Winona City Council unanimously authorized a grant agreement for $7,000 to go towards surveying businesses and others in Winona to gauge the level of knowledge people have regarding those with dementia and promotion of the efforts to make Winona ‘dementia friendly.’”